Matrix metalloproteinases (MMPs) have been the subject of intense research because of
their roles in tumor metastasis and in the rise and spread of degenerative diseases such as
osteo-and rheumatoid arthritis. A preliminary class of 140 druglike, small-molecule matrix
metalloproteinase-3 inhibitors, intended as starting scaffolds for optimization and synthesis,
has been designed in silico using a series of highly predictive three-dimensional
quantitative structure− activity relationship models, including comparative molecular field …